IOVA has climbed more than 400% from its low. Can lung cancer turn Amtagvi into a much bigger franchise?
Iovance approaches new lung cancer data as Amtagvi revenue hits $91 million and IOVA trades near a 52-week high after a major 2026 rally.
Pharma & Biotech